Small

Zacks Small Cap Research – SNGX: Presentation Highlights HyBryte Potential in CTCL… – Go Health Pro

by
Zacks Small Cap Research – SNGX: Presentation Highlights HyBryte Potential in CTCL… – Go Health Pro

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Presentation Highlights HyBryte Potential in CTCL In January 2025, Dr. Neal Bhatia presented at two dermatology conferences on “Off-Label Uses of PDT” (photodynamic therapy). Dr. Bhatia is the Director of Clinical Dermatology at Therapeutics Clinical Research, a member of Soligenix’s (NASDAQ:SNGX) scientific … Read more

Graduating Clients The Right Way: A Thoughtful Approach To Sustainably Transition ‘Small’ Clients To On-Demand – Go Health Pro

by
Graduating Clients The Right Way: A Thoughtful Approach To Sustainably Transition ‘Small’ Clients To On-Demand – Go Health Pro

Early in a firm’s life cycle, a founder might take on nearly any client (and their fees) just to generate enough revenue to ‘keep the lights on’. However, as the firm grows, some of those early clients may no longer be profitable to serve – especially if they generate lower fees than newly onboarded clients. … Read more

Zacks Small Cap Research – GRCE: STRIVE-ON Results Reported – Go Health Pro

by

By John Vandermosten, CFA NASDAQ:GRCE READ THE FULL GRCE RESEARCH REPORT Grace Therapeutics, Inc (NASDAQ:GRCE) reported fiscal year (FY) third quarter results following a series of announcements regarding conference participation, the raise of additional capital and results from the Phase III STRIVE-ON trial for GTx-104. The most important information was the data from the Phase … Read more

Zacks Small Cap Research – TELO Announces Breakthrough – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. … Read more

Zacks Small Cap Research – BLRX: Aphexda Transition Progressing – Go Health Pro

by
Zacks Small Cap Research – BLRX: Aphexda Transition Progressing – Go Health Pro

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) continues its commercialization transition activities for Aphexda as responsibilities for marketing shift from BioLine’s internal team to Ayrmid’s subsidiary Gamida Cell. Gamida cell is commercializing Omisirge, a cell therapy for treating blood cancers in patients who need a stem cell transplant. … Read more

x